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Abstract
A better understanding of the association between diabetes and pancreatic cancer (PC) may inform 
prevention and/or early detection strategies. Metformin has been associated with reduced risk of 
certain cancers, including PC, in some observational clinical studies. We assessed whether 
metformin use was associated with PC risk among those with type 2 diabetes (DM2), and whether 
metformin use modulated the association between DM2 and risk of PC. In total, 536 PC cases and 
869 frequency-matched controls were recruited predominantly from University of California San 
Francisco medical clinics from 2006–2011. Eligible participants completed direct interviews using 
a structured risk factor questionnaire. The association between metformin use and PC risk was 
assessed using propensity score weighted unconditional logistic regression methods in analyses 
restricted to diabetics and adjusted multivariable logistic models in the total study population. 
Ever use of metformin was not associated with PC risk in analyses restricted to DM2 (N=170) 
participants (adjusted OR: 1.01, 95%CI: 0.61–1.68). In the total study population (N=1405) using 
non-diabetics as the referent group, PC risk was inversely associated with diabetes duration 
(ptrend<0.001). Further, when DM2 participants were grouped by ever/never use of metformin and 
compared with non-diabetics, metformin use did not affect the association between DM2 and PC 
risk (never users: OR: 1.44, 95%CI: 0.78–2.67; ever users: OR: 1.19, 95%CI: 0.72–1.99). Results 
from our clinic-based case-control study suggest that metformin use is not associated with PC risk 
among those with DM2 and does not alter the association between DM2 and PC risk.
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Pancreatic cancer (PC) is diagnosed in approximately 45,000 U.S. adults each year, making 
it the ninth most common cancer in women and the tenth most common in men.1 However, 
given its dismal prognosis, PC is the fourth most common cause of cancer-related mortality 
in both sexes, with the lowest 5-year survival rate of all major cancers at 6%.2 With active 
follow up of patients this rate drops to 2%.3 This poor prognosis is partly attributable to 
metastatic disease at diagnosis. Even though genomic evidence suggests that PC cells take at 
least 5 years to develop metastatic capability,4 more than 80% of patients have advanced 
and/or metastatic disease at the time of disease presentation,5 at which point potentially 
curative surgery is not an option. To date, no population-wide screening tool reduces 
mortality associated with this disease. Identifying risk factors and protective factors may 
help in the development of screening programs targeted toward individuals at particularly 
high risk, inform appropriate recommendations regarding modifiable lifestyle habits, and aid 
in PC prevention strategies.
Pancreatic cancer is more common in men than women, among blacks/African Americans 
compared with whites, and increases with age.2 Established factors that increase risk include 
family history and inherited cancer syndromes,6 cigarette smoking,7 hereditary and chronic 
pancreatitis,8,9 obesity,10,11 and diabetes.12 The association between diabetes and the 
development of PC is well established, although the relationship is multifaceted as diabetes 
is both a risk factor for PC and a potential clinical consequence of the disease.13 Metformin, 
an oral biguanide medication used to treat type 2 diabetes, has demonstrated anti-neoplastic 
properties in several preclinical studies.14,15 Metformin may mitigate the PC risk associated 
with diabetes via its hypoglycemic and hypoinsulinemic effects. Hyperinsulinemia leads to 
downregulation of insulin-like growth factor binding protein (IGFBP), increasing free 
insulin-like growth factor 1 (IGF-1).16,17 IGF-1, which normally integrates growth hormone 
signals, is overexpressed in PC and enhances growth in PC cell lines.18 By decreasing blood 
insulin levels, metformin may decrease free IGF-1.14 Tumor suppressive effects also may be 
attributed to inhibition of the mammalian target of rapamycin (mTOR),19 a signaling 
molecule that regulates cell growth and cell cycling via integration of various mitogenic 
signaling pathways. Furthermore, metformin induces apoptosis in PC cells via caspase 
activation and inhibition of the tumorigenic epidermal growth factor receptor (EGFR/
MAPK) pathway.20 Given its various mechanisms of action, the role of metformin as a 
potential cancer protective agent has been evaluated in multiple epidemiologic studies, and 
has been found to be associated with decreased risk of development of breast, colorectal, 
liver, and lung cancers.21–23
Results from studies that evaluated the association between metformin and PC risk have 
been inconsistent, with reduced risk in some24–26 and no effect in others.27–31 A summary 
evaluation of these studies is complicated by differences in study design and methodology, 
including use of different comparison arms, adjustment for different confounders, and 
confounding by indication in analyses of populations that included participants with and 
without diabetes. A recent meta-analysis of nine studies showed a reduction in PC risk with 
metformin use, although there was significant study heterogeneity.21 When stratified by 
study design, analyses indicated a null effect of metformin vs. no metformin use, with an 
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inverse association observed only when metformin was compared with insulin or 
sulfonylurea use. No prospective randomized studies have been conducted to address this 
association, although two randomized controlled trials of diabetes therapy32 were 
secondarily analyzed to assess the effect of metformin on cancer risk. However, the low 
incidence of PC in these studies (20 cases over ~39,000 person years) resulted in an 
imprecise estimate that was not different from null.21 In the present study, we analyzed data 
collected from a large clinic-based case-control study to further clarify the relationship 
between metformin use, diabetes, and PC risk.
Materials and Methods
Study Population
A case-control study of PC conducted at the University of California, San Francisco (UCSF) 
included patients diagnosed with exocrine adenocarcinoma of the pancreas from 2006–2011. 
Patients were recruited from the UCSF Gastrointestinal Medical and Surgical Oncology 
clinics with supplemental recruitment of patients from California Pacific Medical Center 
Medical and Surgical Oncology clinics as well as from the Cancer Prevention Institute of 
California’s early case ascertainment. Eligible patients were 21–85 years old at diagnosis 
and able to complete a direct interview in English. Diagnoses were confirmed by patients’ 
medical records, cancer registry and Surveillance Epidemiology and End Results abstracts 
that include histologic confirmation of diagnoses. Controls were recruited from the UCSF 
General Medicine Primary Care clinics and were frequency-matched to cases by sex and age 
in 5-year groups. Eligibility criteria for controls were the same as for cases with the 
exception of PC diagnoses. In total, 536 cases and 869 controls were eligible and completed 
the interview for a participation rate of 72% for eligible cases and 53% for eligible controls. 
All participants provided informed consent for interview and accession of medical record 
data pertaining to their pancreatic condition and for follow-up contact. The study was 
approved by UCSF’s Committee on Human Research (ID: 10-00503, re-approved 
10/14/2013).
Data collection
Data were collected during direct interviews using a main risk factor questionnaire and the 
Block Brief 2000 food-frequency questionnaire. Participants were queried about 
demographic characteristics and various known or suspected PC risk factors, including 
recent and past weight/height, lifestyle factors such as cigarette smoking, alcohol use and 
diet, and personal and family medical history. Information about most exposures was 
restricted to a referent date of one or more years before diagnosis (cases) or interview 
(controls). Relevant to these analyses, participants were asked whether, more than one year 
before diagnosis (cases) or interview (controls), they had ever been diagnosed with diabetes 
by a physician, the type of diabetes, and their age at diagnosis. Cue cards with brand and 
generic medication names were used to help facilitate recall of medication use. Data 
pertaining to medications taken at least 4 days per week for at least 3 months were recorded 
including drug name, ages first and last used, and duration of use. In-person interviews were 
conducted with 67% and telephone interviews with 16% of participants, while 17% of 
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interviews were started in person and finished over the telephone. No proxy interviews were 
conducted.
Statistical analysis
All statistical analyses were conducted using SAS software v9.3 (SAS Institute, Inc., Cary, 
NC). Preliminary analyses of the association between discrete or continuous factors of 
interest and disease status were conducted using parametric and non-parametric statistics 
including t-test and Wilcoxon rank-sum test. Continuous factors also were evaluated as 
categorical variables based on established groups or quantiles of the distribution among 
controls and similarly assessed using a χ2 test. Collinearity between potential confounding 
variables was examined using Spearman rank-order correlation. Age at PC diagnosis (cases) 
or interview (controls) was grouped as ≤50, 51–60, 61–70, >70 years old. Body mass index 
(BMI) was computed as usual adult weight/height2 (kg/m2) and grouped per World Health 
Organization categories as normal/underweight (BMI <25), overweight (BMI: 25–30) and 
obese (BMI >30). Alcohol consumption was analyzed as average drinks/week over the past 
10 years and cigarette smoking status as never smoker, quit>15y ago, quit 1–15y ago, quit 
<1y ago/current smoker. Ethnicity was analyzed as a dichotomous variable: non-Hispanic 
white and all other ethnic groups.
Here we address the hypotheses that 1) in the population of patients with type 2 diabetes, 
those who use metformin are less likely to develop PC; and 2) the risk for PC associated 
with diabetes is attenuated among patients who use metformin. Thus, analyses of diabetes 
were restricted to patients who reported diagnosis of type 2 diabetes (N=170); 11 patients 
with type 1 diabetes were excluded from these analyses. Duration of diabetes was grouped 
in 5-year increments based on disease biology and data from the published literature, which 
also ensured adequate group sample size for analyses. The association between PC risk and 
specific classes of diabetes medications were assessed in non-mutually exclusive groups 
based on never-ever use. Unconditional logistic regression models, adjusted for matching 
factors and other diabetes medication use, were used to compute odds ratios (OR) with 95% 
confidence intervals as estimates of relative risk. Mediation of the association of BMI and 
PC through diabetes was assessed in stratified and conditional analyses.33
Because of the restricted sample size and to increase causal inference, the relationship 
between metformin use and PC risk in the subgroup of patients with diabetes was evaluated 
using propensity score methods to adjust for potential confounders. Propensity score model 
fit was assessed using area under a receiver operating curve for metformin never/ever use 
and Akaike Information Criteria for analyses of metformin duration. Adequate performance 
of the propensity score model was assessed by examining whether each covariate used to 
model the score was balanced between metformin exposure groups. Analysis of never/ever 
use was limited to the 161 diabetes patients (77 cases, 84 controls) who fit exchangeability 
criteria i.e. patients who used metformin could be “exchanged” with non-users based on 
their covariate profile. The propensity score for never-ever use of metformin included age, 
sex, race, BMI, history of pancreatitis, alcohol, smoking, family history of PC, and other 
diabetes drugs. Duration of metformin use was independently analyzed as a continuous 
variable and as quartiles of duration. A separate propensity score was estimated for the 
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ordinal duration variable, utilizing all 170 diabetic participants. The propensity score for 
duration of metformin use modeled the same factors as for metformin never-ever. Finally, 
unconditional logistic regression models, weighted by the inverse probability of each 
participant being in a given exposure group based on propensity score34–36 were used to 
estimate adjusted ORs for level of metformin duration. To test the broader question of the 
effect of metformin use on diabetes-associated PC risk, standard multivariable unconditional 
logistical regression techniques were used. Non-diabetics were used as the referent group 
and models were adjusted for the same factors included in the propensity score. Linear trend 
in odds ratios was determined based on the Wald chi-square statistic for the factor when 
included as an ordinal variable in multivariable unconditional logistic models. Effect 
modification by sex was explored in stratified analyses. Stratification did not materially 
change point estimates but weakened precision, thus combined analyses are presented.
Raw data are not tabled for analyses with fewer than 5 participants in a cell. All models 
were adjusted for matching factors, age and sex. All statistical tests were two-sided and 
considered statistically significant when p<0.05.
Results
In total, 1405 participants (536 cases and 869 controls) completed interviews and were 
included in these analyses (Table 1). Men constituted 53.0% of cases and 48.3% of controls. 
Cases were slightly older, with a median age of 63 years vs 60 years for controls. Most 
participants (85.2%) were non-Hispanic white, and roughly half (50.2% cases, 45.7% 
controls) were overweight or obese. Frequencies of cigarette smoking were identical, with 
51.1% of cases and controls ever having smoked. Cases were more likely to have consumed 
alcohol, have pancreatitis, or have a family member with PC. Type 2 diabetes also was more 
prevalent in cases (15.1% vs 10.2%), a discrepancy driven by markedly different rates of 
recently diagnosed diabetes (7.3% vs 2.7%).
Type 2 diabetics
A majority of type 2 diabetics reported ever having used metformin (66.5%), whereas ever 
use of secretagogues (38.2%), insulin (27.6%), or thiazolidinediones (17.6%) was less 
common (Table 2). Among type 2 diabetics (N=170), results from models conditionally 
adjusted for each type of diabetes medication showed that PC risk was not associated with 
ever use of metformin or any other specific type of diabetes medication (Table 2). When the 
association between PC risk and metformin use was assessed in the propensity score 
adjusted model, the OR for metformin use was closer to the null (OR: 1.01, Table 3). 
Increased total duration of metformin use (in quartiles) was inversely associated with PC 
risk in minimally adjusted models (ptrend=0.02, Table 3), although individual ORs were 
imprecise and not statistically significant. In the propensity score adjusted model, this 
decreased linear trend in PC risk with increased metformin duration was no longer 
statistically significant (ptrend=0.20, Table 3). Preliminary analyses showed a strong 
correlation between duration of diabetes and duration of metformin use among type 2 
diabetics (Spearman rho=0.74, p<0.0001); therefore, the confounding due to diabetes 
duration was evaluated. Including diabetes duration in the propensity score adjusted model 
Walker et al. Page 5













substantially modified the association between duration of metformin use and PC risk 
(ptrend=0.52), particularly for OR estimates for the longest duration of use. All effects 
remained statistically nonsignificant. Stratification by sex revealed no statistically 
significant differences, although small sample sizes limited the analysis.
Type 2 diabetics and non-diabetics
Type 2 diabetes was associated with a 40% increased risk of PC that was attenuated and no 
longer statistically significant in fully adjusted models (OR: 1.28, 95%CI: 0.81–2.00, Table 
4). Increased duration of diabetes was inversely associated with PC risk, with statistically 
significant elevated ORs limited to those with diabetes of short disease duration (1–5 years 
versus no diabetes OR: 2.47, 95%CI: 1.25–4.85). In fully adjusted models, the increased risk 
of PC among those with diabetes of short duration (1–5 years) was modestly attenuated 
(Table 4) whereas those with longstanding diabetes (10 years or longer) were less likely to 
be diagnosed with PC (OR: 0.44, 95%CI: 0.18–1.08). Metformin use did not confound the 
association of diabetes with PC; ORs did not differ for diabetics who never and ever had 
used metformin (p=0.57, Table 5a). Stratification by sex revealed no significant variation in 
PC risk. Analyses of diabetes duration stratified by duration of metformin use were 
constrained by small numbers in some cells, but again showed increased risk of PC limited 
to those with diabetes of short duration (Table 5b). Few exposed participants precluded our 
ability to robustly assess whether duration of metformin use altered the association between 
longstanding diabetes and PC risk (Table 5b).
Discussion
This case-control study addresses two unresolved areas of research: the association between 
metformin use and PC risk among type 2 diabetics, and the effect of metformin use on 
diabetes-associated PC risk compared to a non-diabetic population. Our data do not support 
a relationship between metformin and PC risk within either study context. Specifically, we 
did not identify any association between ever use of metformin and change in PC risk 
among type 2 diabetics. In a minimally adjusted model, duration of metformin exposure was 
statistically significantly and inversely associated with PC risk. However, propensity score 
weighting for significant confounders eliminated this relationship. Moreover, stratification 
of diabetics by never-ever metformin use or duration of metformin exposure revealed no 
statistically significant association between metformin and diabetes-related PC risk, 
although small sample size in some categories precluded robust conclusions.
Previous case-control studies that investigated the association between metformin use and 
PC risk have focused on slightly different research hypotheses. In a U.S. study, Li and 
colleagues investigated the association between metformin use and PC risk and focused their 
analyses on the subgroup of diabetics in their study population. These investigators 
demonstrated a reduced risk of PC among those who had ever used metformin (OR: 0.38 
95%CI: 0.22–0.69), noting an exceptionally low risk (OR: 0.18 95%CI: 0.09–0.38) among 
those who reported use of metformin for >5 years.26 In contrast, Bodmer et al conducted a 
similar analysis, but inclusive of non-diabetics, within the UK-based General Practice 
Research Database, and found that long-term metformin use (≥30 prescriptions) was not 
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associated with PC risk (OR: 0.87 95%CI: 0.59–1.29).29 However, suggestion of an 
interaction by sex was reported, with a statistically significant decreased PC risk observed 
among women (long-term metformin use OR: 0.43 95%CI: 0.23–0.80). The disparate results 
between these studies may be explained by a number of factors: inclusion or exclusion of 
non-diabetics in the analyses; different control recruitment methods; and adjustment for 
different sets of confounders and for diabetes duration. As such, a direct comparison of 
results between these studies is challenging.
Diabetes is considered a risk factor for PC, a hypothesis supported by data from multiple 
cohort studies and meta-analyses.12,37,38 However, diabetes diagnosed shortly before PC 
diagnosis is very unlikely to be an etiologic factor but rather a consequence of the 
disease,39–41 and inclusion of these cases would bias risk estimates due to misclassification 
of the exposure. Further, causal inference is enhanced by maximizing the likelihood that 
diabetes precedes PC development. For these reasons, diabetes diagnosed within 1 year of 
PC diagnosis (cases) or interview (controls) was not collected in our study, where we 
showed an overall elevated but statistically non-significant risk of PC in participants with 
type 2 diabetes. Of note, previous studies have used varying diabetes duration thresholds to 
categorize participants as pre-diagnosis/interview diabetics,13 and the most appropriate 
classification criteria remain unknown.
Confounding by indication is a concern in studies similar to ours where the effect of interest 
(here metformin) occurs only in the presence of a condition (diabetes) that is associated with 
the outcome of interest (PC). Our analysis incorporated both of the approaches used in 
previously published case-control studies of metformin use and PC risk. Specifically, like Li 
et al, we controlled for confounding by indication by conducting an analysis limited to 
diabetics, addressing the hypothesis that metformin use is associated with decreased PC risk 
in a diabetic population. Similar to Bodmer et al, we also assessed the effect within the total 
population of both diabetics and non-diabetics while adjusting for diabetes duration, testing 
a separate hypothesis that metformin use is associated with decreased PC risk relative to the 
general population.
As with previous observational studies,13,42 we observed an inverse association between 
diabetes duration and PC risk. This effect was driven by a statistically significant increased 
risk in short-term (1–5 years) diabetics, raising the possibility that occult PC may have been 
present for multiple years at the time of diabetes diagnosis in some of the cases, even after 
exclusion of those with diabetes for <1 year. Under the assumption that duration of 
metformin use is likely to be tightly correlated with duration of diabetes, short-term 
metformin use might simply track with short-term (recent-onset) diabetes, and as such 
reflect diabetes caused by PC, in contrast to longer metformin exposure and hence longer-
term diabetes. This would conceivably produce a dose-related association between 
metformin and PC risk that mimics that of diabetes and PC risk. Interestingly, the previous 
analyses by both Li and Bodmer did not formally evaluate the correlation between duration 
of diabetes and metformin use, and used different methods to account for this complicated 
relationship. Li et al analyzed metformin duration in the subset of diabetics with >2 years of 
disease but did not adjust for diabetes duration. The association between long-term 
metformin use and decreased PC risk was lessened but remained statistically significant 
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(OR: 0.18 95%CI: 0.09–0.38 in all diabetics versus OR: 0.30 95%CI: 0.13–0.69 in diabetics 
>2 years). Bodmer et al, in their analysis of those with and without diabetes, also restricted 
diabetes to that diagnosed >2 years before diagnosis but, unlike Li et al, adjusted for 
diabetes duration. Neither study provided estimates of linear correlation between diabetes 
duration and duration of metformin use. In our analysis, duration of diabetes and of 
metformin use were moderately correlated, and controlling for diabetes duration removed 
any suggestion of an association between metformin use and PC risk. The change in risk 
estimate was most notable among long-term users of metformin (≥ 12 years). Thus, our 
results could be interpreted as consistent with those either of Li or of Bodmer, depending on 
which modeling convention we adopted. This highlights how differences in analytic 
approaches can result in seemingly heterogeneous results across studies.
By broadening analyses to the entire study population, we also examined the effect 
modification of metformin use on the association between type 2 diabetes and risk of PC. 
Small sample size precluded our ability to obtain robust estimates in some analyses, but 
overall there was no evidence that ever use or longer use of metformin altered the 
association between diabetes or diabetes duration and PC risk. Stratification by sex likewise 
revealed no significant effect modification. This analysis has been previously conducted in 
only one cohort study, which similarly showed no significant association.24 However, that 
analysis also was statistically limited due to few PC cases (28 total PC cases with diabetes).
Metformin has been hypothesized to decrease PC risk in part through its hypoinsulinemic 
effect.14 Consistent with this theory, secretagogues and exogenous insulin, diabetes drugs 
that induce a hyperinsulinemic state, have been observed to increase PC risk.25,26,29 Though 
use of either of these drug classes trended towards increased PC risk in preliminary analyses, 
relatively few diabetic patients in our study population used these medications, limiting the 
statistical power of our study to assess their effects.
Strengths of this clinic-based case-control study include the large sample size and high case 
participation rate. In a previously conducted population-based study of PC in the San 
Francisco Bay Area, a significant proportion of patients died prior to study contact.3,43,44 In 
the current study, recruitment of patients in the clinic helped minimize the potential for 
survival bias. Detailed information on potential confounding variables was gathered using 
validated questionnaires. Confirmation of diagnoses was obtained from medical records and 
cancer registry data. A rigorous statistical approach to data analysis, including elimination of 
confounding by indication, use of propensity scores and examination of the link between 
metformin duration and diabetes duration, allowed us to optimize the accuracy, precision, 
and causal inference of this study.
Limitations of our analysis include the absence of pharmacy records to confirm duration of 
medication use or medication doses, as well as the potential for recall bias inherent in case-
control studies. Attempts to minimize patient misreporting included direct interviews (no 
proxy interviews) conducted by trained interviewers and the use of cue cards to facilitate 
patient recall. A prospective cohort or randomized controlled design could assuage this bias, 
but the rarity of PC limits the number of cancer diagnoses captured in these types of studies. 
Therefore, case-control data examining PC risk should be interpreted in parallel with 
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previously published cohort studies. Additionally, while clinic-based enrollment 
theoretically minimizes survival bias, the setting of this study at an academic center could 
potentially limit generalizability to the entire population. For example, many PC patients are 
referred to UCSF for surgery, salvage treatment, or potential clinical trial enrollment; these 
therapeutic options necessitate good functional status, and thus UCSF patients may, on 
average, be healthier relative to the general population of PC patients. We also note that the 
prevalence of smoking was lower in our cases than in a previous population-based study 
conducted in the same geographic area,45 and that the representation of Caucasian patients 
in our analysis was disproportionately high. Finally, despite the large sample size, small 
numbers of patients restricted some of our detailed analyses, including careful evaluation by 
sex.
In conclusion, results from this San Francisco clinic-based case-control study do not support 
an association between metformin use and PC risk in type 2 diabetics. Similarly, use of 
metformin by type 2 diabetics had no significant effect on the estimated PC risk associated 
with diabetes relative to the non-diabetic population. Further validation of these findings is 
warranted in larger studies or in pooled analyses, such as through the international pancreas 
case-control consortium (PanC4).
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Metformin has been hypothesized to possess anti-neoplastic properties, but whether it 
decreases pancreatic cancer risk remains uncertain. In this large case-control study, 
metformin use neither altered pancreatic cancer risk among type 2 diabetics nor 
modulated the diabetes/pancreatic cancer risk relationship. The authors further highlight 
differences in analytic techniques that may help explain inconsistencies between 
previously reported results. This work provides evidence against an association between 
metformin use and pancreatic cancer.
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Table 1
Sociodemographic characteristics for 536 pancreatic cancer (PC) cases and 869 controls in a San Francisco 
clinic-based case-control study of pancreatic cancer.
Cases (%) N=536 Controls (%) N=869
Sex
 Male 284 (53.0) 420 (48.3)
 Female 252 (47.0) 449 (51.7)
Age
 ≤50 70 (13.0) 159 (18.3)
 51–60 142 (26.5) 299 (34.4)
 61–70 178 (33.2) 244 (28.1)
 >70 146 (27.2) 167 (19.2)
Race
 Caucasian 453 (84.5) 744 (85.6)
 Non-Caucasian 83 (15.5) 125 (14.4)
BMI
 ≤25 267 (49.8) 472 (54.3)
 25–<30 205 (38.3) 265 (30.5)
 ≥30 64 (11.9) 132 (15.2)
Cigarette Smoking
 Never Smoker 262 (48.9) 425 (48.9)
 Quit >15 years ago 147 (27.4) 248 (28.5)
 Quit 1–15 years ago 57 (10.6) 91 (10.5)
 Current Smoker 70 (13.1) 105 (12.1)
Weekly Alcohol Use
 Non-drinker 190 (35.4) 347 (39.9)
 1–7 drinks/week 221 (41.2) 362 (41.7)
 8–14 drinks/week 71 (13.3) 67 (7.7)
 15–21 drinks/week 29 (5.4) 35 (4.0)
 ≥22 drinks/week 25 (4.7) 58 (6.7)
Pancreatitis1
 No 496 (92.7) 852 (98.0)
 Yes 39 (7.3) 17 (2.0)
Family History of PC
 No 507 (94.6) 835 (96.1)
 Yes 29 (5.4) 34 (3.9)
Type 2 Diabetes
 No 455 (84.9) 780 (89.8)
 Yes 81 (15.1) 89 (10.2)
Diabetes Duration
 None 455 (84.9) 780 (89.8)
 1–<5 years 39 (7.3) 23 (2.7)
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Cases (%) N=536 Controls (%) N=869
 5–<10 years 19 (3.5) 25 (2.9)
 ≥10 years 23 (4.3) 41 (4.7)
1
Unknown: N=1.
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Table 2
ORs and 95%CIs for pancreatic cancer related to type-2 diabetes medication use in a San Francisco clinic-
based case-control study of pancreatic cancer.
Cases (%) N=81 Controls (%) N=89 OR1 (95% CI)
Metformin
 No 28 (34.6) 29 (32.6) 1.00
 Yes 53 (65.4) 60 (67.4) 0.81 (0.42–1.58)
Insulin Secreteagogues
 No 49 (60.5) 56 (62.9) 1.00
 Yes 32 (39.5) 33 (37.1) 1.12 (0.58–2.14)
Thiazoladinediones
 No 67 (82.7) 73 (82.0) 1.00
 Yes 14 (17.3) 16 (18.0) 0.80 (0.35–1.86)
Insulin
 No 56 (69.1) 67 (75.3) 1.00
 Yes 25 (30.9) 22 (24.7) 1.48 (0.74–2.99)
1
Adjusted for age, sex, and other classes of diabetes drugs.
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Table 4
ORs and 95%CIs for pancreatic cancer related to type 2 diabetes and duration of diabetes in a San Francisco 
clinic-based case-control study of pancreatic cancer.
Cases (%) Controls (%) OR1 (95%CI) OR2 (95%CI)
Type 2 Diabetes (>1 yr)
 No 455 (84.9) 780 (89.8) 1.00 (ref) 1.00 (ref)
 Yes 81 (15.1) 89 (10.2) 1.41 (1.02–1.96) 1.28 (0.81–2.00)
Diabetes Duration
 1 – 5 years 39 (7.3) 23 (2.7) 2.75 (1.62–4.69) 2.47 (1.25–4.85)
 5 – 10 years 19 (3.5) 25 (2.9) 1.21 (0.65–2.23) 0.80 (0.34–1.87)
 >10 years 23 (4.3) 41 (4.7) 0.81 (0.47–1.38) 0.44 (0.18–1.08)
  P for trend <0.001 <0.001
1
Adjusted for age and sex
2
Adjusted for age, sex, race, BMI, history of pancreatitis, alcohol, smoking, family history of PC, diabetes drugs.
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